Inhibitors of the histone deacetylase HDAC3 have been shown to be effective in reversing AD pathologies, specifically dephosphorylation of tau and decreased levels of Aβ proteins, in triple transgenic mice (Janczura et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.